Cognitive Deficits
Conditions
Brief summary
In the present study, a long-term cognitive follow-up of participants of the BioCog cohort (data collection period 2014 - 2019, Ethical vote No: EA2/092/14) from the Berlin study center is to be will be performed in order to record long-term cognitive sequelae (7 to 10 years after study inclusion). In addition to a medical telephone/video visit, the follow-up includes the collection of cognitive tests via web applications and questionnaires of acceptance and usability in the home environment. The study data are analysed in cooperation with the University of Bonn, University Medical Center Schleswig-Holstein and the University of Essen.
Detailed description
The primary research objective is the exploratory investigation of changes in cognitive test performance as well as cognitive self-care and functionality in former BioCog patients and BioCog subjects in the non-surgical comparison cohort in the long-term follow-up (7 - 10 years) compared to the baseline survey (from the BioCog main study).The primary question is operationalized in several ways: * according to the International Statistical Classification of Diseases and Related Health Problems(ICD-10) classification system * according to the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) classification system * computer-based, online and independently conducted cognitive testing using Cantab Web based testing from Cambridge Cognition * Cognitive self-care using Geriatric depression Scale item 10 * Cognitive self-care with Multifactorial Memory Questionnaire * Cognitive other-care with The Informant Questionnaire on Cognitive Decline in the Elderly questionnaire * Functionality with Activities of Daily Living (ADLs) & Instrumental Activities of Daily Living (IADLs) questionnaire * Additionally: Quality of life with 5-level EQ-5D version (EQ-5D-5L) Evaluation by Mild Cognitive Impairment Algorithm of the University Clinic Bonn (research group Prof. Wagner). Evaluation by mild/major Neurocognitive Disorder (NCD) algorithm of Charité - University Medicine Berlin (research group Prof. Spies)
Interventions
None listed
Sponsors
Charite University, Berlin, Germany
University Hospital, Bonn
University Hospital Schleswig-Holstein
Universitätsklinikum Essen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients Inclusion Criteria: * Patients of Berliner BioCog cohort with cognitive Testing (CANTAB Research Suite) at Baseline and with plasma samples for baseline that can be contacted. * Written informed consent for participation in the BioCog-Web study. * Data and reserve samples from patients in the Berlin BioCog cohort who can no longer be contacted.
Exclusion criteria
* None Subjects Inclusion Criterion: -BioCog subjects of the non-operated comparison cohort from Berlin with cognitive testing (CANTAB Research Suite) at baseline who are contactable
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in cognitive performance | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | The primary object of research is the explorative investigation of the change in cognitive test performance as well as cognitive self-care and functionality in the long-term follow-up (7 - 10 years) compared to the baseline survey (from the main BioCog study). It is measured with CANTAB Research Suite, CANTAB web-based testing and paper pencil tests. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acceptance | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | Acceptance of the CANTAB web-based testing of Cambridge Cognition is measured with a questionnaire. |
| Usability | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | Usability of the CANTAB web-based testing of Cambridge Cognition is measured with a questionnaire. |
| NUcleic acid Linked Immuno-Sandwich Assay Central Nervous System Disease Multiplex Panel | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | Analysis of 120 proteins. |
| New diagnoses | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | Last doctor's letter/last findings (especially in the case of neurological/psychiatric/geriatric connections - e.g. memory consultation) for recording new diagnoses and recording the last outpatient and/or inpatient treatments. |
| Actual medication | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | Current comedication and supplements |
| Charlson Comorbidity index | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | Comorbidity |
| History of Falls | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | History of falls is measured with the question: Have you had a fall event within the last year? |
| Depression | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | Depression is measured with Geriatric Depression Scale. |
| Weight history | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | Weight history is measured by weight change in the past 3-6 months. |
| Malnutrition Universal Screening Tool (MUST)-Score | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | Add Scores together to calculate overall risk of malnutrition with the Malnutrition screening tool: Score 0 corresponds to low risk; Score 1 corresponds to medium risk; Score 2 or more corresponds to high risk. |
| Body mass index (BMI) | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | BMI is a calculated measure of a person's body weight (in kilograms) divided by the square of their height (in meters). |
| Mortality | Participants will be followed for sequelae at 7-10 years after BioCog study inclusion | Mortality is measured by the number of deaths. |
Countries
Germany
Contacts
PRINCIPAL_INVESTIGATORClaudia Spies, MD, Prof.
Charitè - University Berlin
Outcome results
None listed